NCT06153251 2026-03-18
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Celgene
Celyad Oncology SA